

Beat Mullhaupt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6712133/publications.pdf>

Version: 2024-02-01

95
papers

5,066
citations

172457

29
h-index

91884

69
g-index

104
all docs

104
docs citations

104
times ranked

8373
citing authors

#	ARTICLE	IF	CITATIONS
1	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	8.1	1,619
2	Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 685-697.	9.1	402
3	HOPE for human liver grafts obtained from donors after cardiac death. <i>Journal of Hepatology</i> , 2014, 60, 765-772.	3.7	278
4	Symptoms of Depression and Anxiety Are Independently Associated With Clinical Recurrence of Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 829-835.e1.	4.4	260
5	Alveolar echinococcosis: From a deadly disease to a well-controlled infection. Relative survival and economic analysis in Switzerland over the last 35 years. <i>Journal of Hepatology</i> , 2008, 49, 72-77.	3.7	215
6	Challenges to Liver Transplantation and Strategies to Improve Outcomes. <i>Gastroenterology</i> , 2015, 148, 307-323.	1.3	208
7	Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis score and aspartate aminotransferase-platelet ratio index. <i>Liver International</i> , 2017, 37, 369-376.	3.9	207
8	Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals. <i>Gastroenterology</i> , 2018, 154, 976-988.e4.	1.3	132
9	A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer Development. <i>Cancer Cell</i> , 2017, 32, 342-359.e10.	16.8	122
10	Reduced IFN-4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. <i>Nature Communications</i> , 2014, 5, 5699.	12.8	117
11	Targeting senescent cholangiocytes and activated fibroblasts with B cell lymphoma extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2 ^{-/-}) mice. <i>Hepatology</i> , 2018, 67, 247-259.	7.3	99
12	Liver Allograft Failure After Nivolumab Treatment—A Case Report With Systematic Literature Research. <i>Transplantation Direct</i> , 2018, 4, e376.	1.6	98
13	Correlation between Dual-Energy and Perfusion CT in Patients with Hepatocellular Carcinoma. <i>Radiology</i> , 2016, 280, 78-87.	7.3	65
14	Sofosbuvir/velpatasvir for 12 weeks in genotype 1 HCV-infected liver transplant recipients. <i>Journal of Hepatology</i> , 2018, 69, 603-607.	3.7	58
15	Secondary sclerosing cholangitis as cause of persistent jaundice in patients with severe COVID-19. <i>Liver International</i> , 2021, 41, 2404-2417.	3.9	58
16	Hot topics in liver transplantation: Organ allocation “ extended criteria donor “ living donor liver transplantation. <i>Journal of Hepatology</i> , 2008, 48, S58-S67.	3.7	52
17	Outcome after Discontinuing Long-Term Benzimidazole Treatment in 11 Patients with Non-resectable Alveolar Echinococcosis with Negative FDG-PET/CT and Anti-Em11/3-10 Serology. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003964.	3.0	52
18	Canonical NF- κ B signaling in hepatocytes acts as a tumor suppressor in hepatitis B virus surface antigen-driven hepatocellular carcinoma by controlling the unfolded protein response. <i>Hepatology</i> , 2016, 63, 1592-1607.	7.3	51

#	ARTICLE	IF	CITATIONS
19	Visualization of hepatitis E virus RNA and proteins in the human liver. <i>Journal of Hepatology</i> , 2017, 67, 471-479.	3.7	49
20	Pathology of Echinococcosis. <i>American Journal of Surgical Pathology</i> , 2020, 44, 43-54.	3.7	46
21	Simulation of hepatitis C based on a mandatory reporting system. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 25-34.	1.6	41
22	Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1114-1120.	1.5	41
23	Is tumor biopsy necessary?. <i>Liver Transplantation</i> , 2011, 17, S14-S25.	2.4	38
24	Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy. <i>PLoS ONE</i> , 2015, 10, e0138838.	2.5	38
25	Polymorphisms in the lectin pathway of complement activation influence the incidence of acute rejection and graft outcome after kidney transplantation. <i>Kidney International</i> , 2016, 89, 927-938.	5.2	37
26	A systematic review and meta-analysis of HCV clearance. <i>Liver International</i> , 2017, 37, 1431-1445.	3.9	37
27	Molecular detection of hepatitis E virus (HEV) in liver biopsies after liver transplantation. <i>Modern Pathology</i> , 2015, 28, 523-532.	5.5	36
28	Cost-Effectiveness Analysis of Sofosbuvir Compared to Current Standard Treatment in Swiss Patients with Chronic Hepatitis C. <i>PLoS ONE</i> , 2015, 10, e0126984.	2.5	36
29	Epidemic cystic and alveolar echinococcosis in Kyrgyzstan: an analysis of national surveillance data. <i>The Lancet Global Health</i> , 2020, 8, e603-e611.	6.3	35
30	A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. <i>Journal of Hepatology</i> , 2022, 76, 275-282.	3.7	33
31	Late biliary complications in human alveolar echinococcosis are associated with high mortality. <i>World Journal of Gastroenterology</i> , 2014, 20, 5881.	3.3	26
32	Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfecting men who have sex with men. <i>Journal of Hepatology</i> , 2016, 65, 26-32.	3.7	26
33	A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance. <i>Hepatology</i> , 2015, 62, 1375-1387.	7.3	25
34	Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland. <i>PLoS ONE</i> , 2015, 10, e0125214.	2.5	25
35	Hepatitis E virus as a cause of acute hepatitis acquired in Switzerland. <i>Liver International</i> , 2018, 38, 619-626.	3.9	25
36	Successful use of the Molecular Adsorbent Recirculating System (MARS) in a patient with primary biliary cirrhosis (PBC) and treatment refractory pruritus. <i>Hepatology Research</i> , 2003, 25, 442-446.	3.4	24

#	ARTICLE	IF	CITATIONS
37	Alterations in Enterohepatic Fgf15 Signaling and Changes in Bile Acid Composition Depend on Localization of Murine Intestinal Inflammation. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2382-2389.	1.9	21
38	Genetic diversity of <i>Echinococcus multilocularis</i> and <i>Echinococcus granulosus sensu lato</i> in Kyrgyzstan: The A2 haplotype of <i>E. multilocularis</i> is the predominant variant infecting humans. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008242.	3.0	19
39	A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients. <i>PLoS ONE</i> , 2015, 10, e0133028.	2.5	18
40	Development of OXY111A, a novel hypoxia-modifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms - Protocol of a first Ib/IIa clinical trial. <i>BMC Cancer</i> , 2016, 16, 812.	2.6	18
41	Recurrence of Hepatitis B Infection in Liver Transplant Patients Receiving Long-Term Hepatitis B Immunoglobulin Prophylaxis. <i>Annals of Transplantation</i> , 2018, 23, 789-801.	0.9	17
42	HCV disease burden and population segments in Switzerland. <i>Liver International</i> , 2022, 42, 330-339.	3.9	14
43	Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3349-3358.	3.0	13
44	Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?. <i>PLoS ONE</i> , 2018, 13, e0209374.	2.5	12
45	Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection. <i>Journal of Viral Hepatitis</i> , 2020, 27, 974-986.	2.0	12
46	Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1–3 Infections. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 195-198.e2.	4.4	12
47	Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030. <i>Swiss Medical Weekly</i> , 2017, 147, w14543.	1.6	12
48	Evaluation of a structured treatment discontinuation in patients with inoperable alveolar echinococcosis on long-term benzimidazole therapy: A–retrospective cohort study. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010146.	3.0	11
49	Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Infection and Advanced Liver Fibrosis or Cirrhosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1282-1291.	3.2	10
50	Evaluation of kinase-inhibitors nilotinib and everolimus against alveolar echinococcosis in–vitro and in a mouse model. <i>Experimental Parasitology</i> , 2018, 188, 65-72.	1.2	10
51	Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland. <i>Swiss Medical Weekly</i> , 2018, 148, w14560.	1.6	10
52	Liver cancer with concomitant TP53 and CTNNB1 mutations: a case report. <i>BMC Clinical Pathology</i> , 2016, 16, 7.	1.8	9
53	Characteristics of Foreign-Born Persons in the Swiss Hepatitis C Cohort Study: Implications for Screening Recommendations. <i>PLoS ONE</i> , 2016, 11, e0155464.	2.5	9
54	Influence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection. <i>PLoS ONE</i> , 2016, 11, e0158512.	2.5	9

#	ARTICLE	IF	CITATIONS
55	Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland. <i>Swiss Medical Weekly</i> , 2015, 145, w14221.	1.6	8
56	Fatal Liver and Lung Alveolar Echinococcosis with Newly Developed Neurologic Symptoms due to the Brain Involvement. <i>The Surgery Journal</i> , 2016, 02, e83-e88.	0.7	7
57	Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions. <i>Swiss Medical Weekly</i> , 2019, 149, w14694.	1.6	7
58	Serological Assays for Alveolar and Cystic Echinococcosis – A Comparative Multi-Test Study in Switzerland and Kyrgyzstan. <i>Pathogens</i> , 2022, 11, 518.	2.8	7
59	Identification of an Endoglin Variant Associated With HCV-Related Liver Fibrosis Progression by Next-Generation Sequencing. <i>Frontiers in Genetics</i> , 2019, 10, 1024.	2.3	6
60	Recanalization of Chronic Noncirrhotic, Nonmalignant Splanchnic Thromboses is Feasible: A Transsplenic Assisted Patient-Tailored Approach. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, 1377-1385.	0.5	6
61	Orbital Pseudotumor as a Rare Extrahepatic Manifestation of Hepatitis C Infection. <i>Case Reports in Gastroenterology</i> , 2016, 10, 113-119.	0.6	5
62	Hepatitis E blood donor screening – “More than a mere drop in the ocean?”. <i>Journal of Hepatology</i> , 2018, 69, 8-10.	3.7	5
63	Association between environmental and climatic risk factors and the spatial distribution of cystic and alveolar echinococcosis in Kyrgyzstan. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009498.	3.0	5
64	Pilot Sub-Study of the Effect of Hepatitis C Cure by Glecaprevir/Pibrentasvir on the Gut Microbiome of Patients with Chronic Hepatitis C Genotypes 1 to 6 in the Mythen Study. <i>Pharmaceuticals</i> , 2021, 14, 931.	3.8	5
65	ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection. <i>PLoS ONE</i> , 2015, 10, e0144004.	2.5	5
66	5- ² -Cytosine DNA-methyltransferase mRNA levels in hereditary colon carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1999, 434, 57-62.	2.8	4
67	A significant effect of the killer cell immunoglobulin-like receptor ligand human leucocyte antigen on fibrosis progression in chronic C hepatitis with or without liver transplantation. <i>Liver International</i> , 2016, 36, 1331-1339.	3.9	4
68	Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study. <i>PLoS ONE</i> , 2019, 14, e0218706.	2.5	4
69	A rare cause of a cholestatic jaundice in a North African teenager. <i>Liver International</i> , 2019, 39, 2036-2041.	3.9	4
70	Human genomics of acute liver failure due to hepatitis B virus infection: An exome sequencing study in liver transplant recipients. <i>Journal of Viral Hepatitis</i> , 2019, 26, 271-277.	2.0	4
71	Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland. <i>Swiss Medical Weekly</i> , 2021, 151, w20399.	1.6	4
72	Adherence to, and patient convenience of, prolonged-release tacrolimus in stable kidney and liver transplant recipients after conversion from immediate-release tacrolimus in routine clinical practice in Switzerland. <i>Swiss Medical Weekly</i> , 2021, 151, w20453.	1.6	4

#	ARTICLE	IF	CITATIONS
73	Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients. PLoS ONE, 2018, 13, e0208225.	2.5	3
74	Characteristics and Clinical Course of Alveolar Echinococcosis in Patients with Immunosuppression-Associated Conditions: A Retrospective Cohort Study. Pathogens, 2022, 11, 441.	2.8	3
75	The ¹³ C-methactin breath test is non-inferior to liver biopsy in predicting liver-related death and transplantation: A 7-year prospective follow-up study in 132 patients with chronic hepatitis C infection. GastroHep, 2020, 2, 344-350.	0.6	2
76	When Echinococcus granulosus transmigrates from the liver into the pericardium: a case report. Journal of Surgical Case Reports, 2021, 2021, rjaa492.	0.4	2
77	Autochthonous hepatitis E as a cause of acute-on-chronic liver failure and death: histopathology can be misleading but transaminases may provide a clue. Swiss Medical Weekly, 2021, 151, w20502.	1.6	2
78	A prospective, multicenter, post-marketing observational study to measure the quality of life of HCV genotype 1 infected, treatment naïve patients suffering from fatigue and receiving 3D regimen: The HEMATITE study. PLoS ONE, 2020, 15, e0241267.	2.5	2
79	Mortality from primary liver cancer in Switzerland from 1975 to 1994. Swiss Medical Weekly, 2008, 138, 313-6.	1.6	2
80	The essential requirements for an HPB centre to deliver high-quality outcomes. Journal of Hepatology, 2022, 77, 837-848.	3.7	2
81	Liver retransplantation with cavoportal hemitransposition after percutaneous mesocaval shunt creation. Liver Transplantation, 2016, 22, 1154-1158.	2.4	1
82	MRI and PET-CT Failed to Differentiate Between Hepatic Malignancy and Brucelloma. Open Forum Infectious Diseases, 2018, 5, ofy052.	0.9	1
83	Protein Tyrosine Phosphatase Nonreceptor Type 2 Expression Does Not Correlate with Viral Load or Response to Direct-Acting Antiviral Therapy in Hepatitis C Virus Infections-Infected Patients. Digestion, 2021, 102, 453-461.	2.3	1
84	Rates of Hepatocellular Carcinoma After Start of Treatment for Chronic Hepatitis C Remain High with Direct Acting Antivirals: Analysis from a Swiss Liver Transplant Center. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 565-574.	3.7	1
85	Infected Extrahepatic Splanchnic Venous Stent(-Grafts): Clinical Presentation, Imaging, and Treatment in Three Patients. Journal of Vascular and Interventional Radiology, 2020, 31, 754-758.	0.5	1
86	Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant. Annals of Hepatology, 2017, 16, 375-381.	1.5	1
87	Reply to Cunha et al. Clinical Infectious Diseases, 2015, 61, 1894-1895.	5.8	0
88	IDDF2018-ABS-0109...SOFOSBUVIR/VELPATASVIR for 12 weeks in genotype 1-4 hcv-infected liver transplant recipients. , 2018, , .		0
89	Increasing prevalence of obesity and diabetes among patients evaluated for liver transplantation in a Swiss tertiary referral center: a 10-year retrospective analysis. , 2022, 152, w30138.		0
90	Title is missing!. , 2020, 15, e0241267.		0

#	ARTICLE	IF	CITATIONS
91	Title is missing!. , 2020, 15, e0241267.		0
92	Title is missing!. , 2020, 15, e0241267.		0
93	Title is missing!. , 2020, 15, e0241267.		0
94	Title is missing!. , 2020, 15, e0241267.		0
95	Title is missing!. , 2020, 15, e0241267.		0